FAST READ
- Biotech Conclave 2026 highlighted gene editing, precision medicine, indigenous biopharma capability and protection of genetic data.
- India already has regulatory guidance for gene-therapy product development and clinical trials involving bodies such as CDSCO, ICMR and DBT.
- The policy challenge is to combine affordable innovation with biosafety, ethics, informed consent and genomic-data protection.
WHY IN NEWS
- Rapid advances in CRISPR, cell and gene therapies are moving biotechnology from broad population treatment toward more personalised interventions.
- India's scale, disease burden and research capacity create opportunity, but genetic data is uniquely sensitive because it is persistent and partly shared with biological relatives.
TOP DATA & FACTS
- Gene editing deliberately alters genetic material at targeted locations.
- CRISPR systems are widely used research tools for targeted editing.
- Precision medicine tailors prevention or treatment using individual biological characteristics.
- Gene therapy may add, silence, replace or edit genetic material.
- India has National Guidelines for Gene Therapy Product Development and Clinical Trials, 2019.
- CDSCO is India's central drug regulator.
- ICMR develops biomedical research and ethical guidance.
- DBT supports biotechnology research and policy.
- India has supported clinical research in gene therapy, including haemophilia.
- Genetic data can reveal disease predisposition and ancestry information.
- Genomic information can have implications for biological relatives, not only the sampled individual.
- Informed consent must address future use, storage and sharing of samples and data.
- Re-identification risk can persist even after simple removal of names.
- Equitable access is important because advanced therapies can be extremely expensive.
- One Health links human, animal and environmental health.
PRELIMS
- CRISPR is a gene-editing technology, not a vaccine platform by definition.
- Precision medicine is broader than gene editing.
- CDSCO regulates drugs; ICMR is a research/ethics institution; DBT promotes biotechnology.
- Somatic editing affects treated body cells; germline editing raises heritable-change concerns.
- Genetic data can remain sensitive over long periods.
- Clinical translation requires both scientific evidence and regulatory oversight.